title: Enteral tube feeding for cystic fibrosis.
abstract: BACKGROUND
  Enteral tube feeding is routinely used in many cystic fibrosis centres when weight for height percentage is less than 85%, when there has been weight loss for longer than a two-month period or when there has been no weight gain for two to three months (under five years old) or for six months (over five years old).
  
  
  OBJECTIVE
  To examine the evidence that in people with cystic fibrosis supplemental enteral tube feeding improves nutritional status, respiratory function, and quality of life without significant adverse effects.
  
  
  METHODS
  We searched the Cochrane Cystic Fibrosis and Genetic Disorders Group Trials Register which comprises references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings. We also contacted the companies that market enteral feeds and reviewed their databases. Date of the most recent search of the Group's Cystic Fibrosis Trials Register: November 2007.
  
  
  METHODS
  All randomised controlled trials comparing supplemental enteral tube feeding for one month or longer with no specific intervention in people with cystic fibrosis.
  
  
  METHODS
  Thirteen trials were identified by the search; however, none were eligible for inclusion in this review.
  
  
  RESULTS
  There are no trials included in this review.
  
  
  CONCLUSIONS
  Supplemental enteral tube feeding is widely used throughout the world to improve nutritional status in people with cystic fibrosis. The methods mostly used, nasogastric or gastrostomy feeding, are invasive, expensive, and may have a negative effect on self-esteem and body image. Reported use of enteral tube feeding suggests that it results in nutritional and respiratory improvement and it is disappointing that their efficacy has not been fully assessed by randomised controlled trials. With the more frequent recommendations to use enteral tube feeding as an early rather than a late intervention, this systematic review identifies the need for a multicentre, randomised controlled trial assessing both efficacy and possible adverse effects of enteral tube feeding in cystic fibrosis. There are no trials included in the review and we have not identified any relevant trials up to November 2007. We therefore do not plan to update this review until new trials are published.
authors.affiliation: Seacroft Hospital, Regional Adult Cystic Fibrosis Unit, York Road, Leeds, UK, LS14 6UH. Steven.Conway@leedsth.nhs.uk
authors.forename: S P
authors.initials: SP
authors.lastname: Conway
authors.forename: A
authors.initials: A
authors.lastname: Morton
authors.forename: S
authors.initials: S
authors.lastname: Wolfe
mesh_terms: D003550:Cystic Fibrosis / Q000628:therapy*; D019587:Dietary Supplements; D004750:Enteral Nutrition; D006801:Humans